Hydrophilic Nasal Gel of Lidocaine Hydrochloride

Abstract

Intranasal lidocaine hydrochloride (LID, CAS 73-78-9) has been widely and commonly used in the treatment of a series of symptoms such as migraine, cluster headache and trigeminal neuralgia in clinical studies. Nevertheless, rapid nasal mucociliary clearance of intranasal solution presents the predominant obstacle impacting its efficiency. In order to prolong the residence time of LID in the nasal cavity and increase its absorption, a LID nasal gel had been developed previously using hydroxypropyl methyl cellulose (HPMC) as base material. The LID nasal gel formulation has been optimized through central composite design and its in vitro release behavior has been investigated. In the present study, safety studies employing in situ toad palate model and in vivo rat nasal mucosa model showed that compared with LID nasal spray, LID nasal gel was less toxic to mucocilia. The pharmacokinetic parameters, along with olfactory and ventricle delivery of LID from nasal gel were compared with those of LID from nasal spray, intravenous injections and oral solutions in rats using microdialysis, and the drug targeting index (DTI) was used to evaluate their brain delivery. The absolute bioavailability of the optimized LID nasal gel was about 1.5 times of that of LID nasal spray which suggested a better absorption of LID from nasal gel. Moreover, the drug targeting index (DTI) of olfactory/ventricle after nasal gel and spray administration was 2.15/1.51 and 1.66/1.26, respectively. This suggested that a fraction of the LID dose could be transported directly from the nasal cavity into the central nervous system (CNS), and the brain delivery of LID can be enhanced by nasal gel.

Key words

Brain delivery - CAS 73-78-9 - Lidocaine hydrochloride - Local anesthetic - Microdialysis - Nasal gel

1st Communication see Arzneimittelforschung 2009;59(11):543–549.

• Literature

• 1 Kudrow L, Kudrow DB, Sandweiss JH. Rapid and sustained relief of migraine attacks with intranasal lidocaine: preliminary findings. Headache. 1995; 35: 79-82
• 2 Maizels M, Geiger AM. Intranasal lidocaine for migraine: a randomized trial and open-label follow-up. Headache. 1999; 39: 543-51
• 3 Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs. 2004; 18: 671-85
• 4 Kanai A, Suzuki A, Kobayashi M, Hoka S. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. Br J Anaesth. 2006; 97: 559-63
• 5 Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000; 11: 1-18
• 6 Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction?. J Drug Target. 1998; 5: 415-41
• 7 Michael IU, Remigius UA, Norbert V, Renaat K. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliver Rev. 2005; 57: 1640-65
• 8 Bagger M, Bechgaard E. A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. Int J Pharm. 2003; 269: 311-22
• 9 Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 3rd ed San Diego (CA): Academic Press; 1997
• 10 Hunt CA, MacGregor RD, Siegel RA. Engineering targeted in vivo drug delivery: I. The physiological and physicochemical principles governing opportunities and limitations. Pharm Res. 1986; 3: 333-44
• 11 Wang F, Jiang XG, Lu W. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm. 2003; 263: 1-7
• 12 Jiang XG, Cui JB, Fang XL, Wei Y, Xi NZ. Toxicity of drugs on nasal mucocilia and the method of its evaluation. Acta Pharm Sin. 1995; 30: 848-53
• 13 Hsieh DS. Drug permeation enhancement: theory and applications. New York: Marcel Dekker; 1994: 350-351
• 14 Zhang Y, Jiang XG, Yao J. Lowering of sodium deoxycholate-induced nasal ciliotoxicity with cyclodextrins. Acta Pharmacol Sin. 2001; 22: 1045-50